Vlad Skutelnik

Macroaxis Contributor

Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
Company Analysis
editors@macroaxis.com

Vlad Skutelnik Latest Stories - Published

Straumann Hld N is scheduled to announce its earnings today. While many of us are getting excited about healthcare space, we are going to digest the feasibility of purchasing Straumann. What exactly are Straumann Hld shareholders getting in September?
  12 hours ago at Macroaxis 
By Vlad Skutelnik
Cemtrex is scheduled to announce its earnings today. Cemtrex Issuance Repayment of Debt Securities is fairly stable at the moment as compared to the past year. Cemtrex reported Issuance Repayment of Debt Securities of 5.11 Million in 2021. Net Cash Flow from Financing is likely to rise to about 5.6 M in 2022, whereas Average Assets are likely to drop slightly above 55.9 M in 2022. While some millenniums are indifferent towards technology space, it makes sense to break down Cemtrex as a unique investment alternative. Let's try to inspect if Cemtrex shares are reasonably priced going into September.
  a day ago at Macroaxis 
By Vlad Skutelnik
Whilst many millenniums are getting more into technology space, it makes sense to break down Cemtrex against current trends within the economy. As expected, Cemtrex is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. A lot of the movements of the company stock price movements has been a reflection of what is happening in the market overall. The appearance of strong basic indicators of the company suggests a short-term price swing for investors of Cemtrex. Cemtrex is scheduled to announce its earnings tomorrow.
  2 days ago at Macroaxis 
By Vlad Skutelnik
It looks like Alphabet will be up for a correction way faster as its share price whent up 2.39% today to Protalix Biotherapeutics's 1.6529%. As many rational traders are trying to avoid healthcare space, it makes sense to break down Protalix Biotherapeutics a little further and understand how it stands against Alphabet and other similar entities. We are going to inspect some of the competitive aspects of both Protalix and Alphabet.
  2 days ago at Macroaxis 
By Vlad Skutelnik
Rockwell Medical Enterprise Value is most likely to increase significantly in the upcoming years. The preceding year's Enterprise Value was reported at 440.88 Million. The current Invested Capital Average is estimated to increase to about 39.8 M, while Net Income Per Employee is projected to decrease to (117.5 K). Today we will concentrate on Rockwell Medical. We will analyze why it could be a much better year for Rockwell Medical shareholders. This post is to show some fundamental factors affecting Rockwell Medical's products and services. I will also lay out how it may impact the investing outlook for Rockwell Medical in September.
  2 days ago at Macroaxis 
By Vlad Skutelnik
Whilst many millenniums are getting more into real estate space, it makes sense to digest Simon Property Group. We will evaluate why recent Simon Property price moves suggest a bounce in September. Is current the entity value sustainable? We will go over the stock valuation drivers to give you a better outlook on taking a position in it.
  3 days ago at Macroaxis 
By Vlad Skutelnik
Lets try to focus on the odds of Medical Properties to fully recover from the latest fall as its shares went up 2.45%. The company current daily volatility is 2.0 percent, with a beta of 0.92 and an alpha of -0.1 over DOW. As many millenniums are excited about health management, it is only fair to focus on Medical Properties Trust. We will analyze why Medical Properties investors may still consider a stake in the business.
  3 days ago at Macroaxis 
By Vlad Skutelnik
Today we may see the proof that Salesforce would recover much slower from the new pull down as its shares went up 1.69% to Embark Technology's 84.4828%. As many rational traders are trying to avoid technology space, it makes sense to examine Embark Technology a little further and understand how it stands against Salesforce and other similar entities. We are going to concentrate on some of the competitive aspects of both Embark and Salesforce.
  3 days ago at Macroaxis 
By Vlad Skutelnik
While some millenniums are indifferent towards consumer cyclical space, it makes sense to sum up China Automotive Sys in terms of its current potentials. As expected, China Automotive is starting to reaffirm its true potential as retail investors are becoming more and more confident in the future outlook. The returns on investing in China Automotive and the market returns of the last few months appear uncorrelated to each other. The record of invariable basic indicators of the enterprise connotes a short-term price swing for retail investors of China. China Automotive Sys is scheduled to announce its earnings today.
  few days ago at Macroaxis 
By Vlad Skutelnik
Bio-Key Intl is scheduled to announce its earnings today. While some baby boomers are getting worried about their positions in industrials space, it is entirely reasonable to concentrate on Bio-Key Intl as a possible position for your existing portfolio. What exactly are Bio-Key Intl shareholders getting in September?
  few days ago at Macroaxis 
By Vlad Skutelnik

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Thematic Ideas
Explore Investing Ideas